Redefining the discovery and development of best-in-class oligonucleotide therapeutics
Our Mission
With OligoCreator®, our AI-empowered drug discovery platform, we deliver on our mission to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
OligoCreator, our AI-empowered drug discovery platform, combines both innovative and proven delivery modalities with the precision and specificity of oligonucleotides.
Global partner of choice for oligonucleotide drug discovery and development programs.
About us
We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator® platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
Mode of Action
Latest News & Events
Secarna Pharmaceuticals to present new data and clinical strategy for lead antisense oligonucleotide program SECN-15 at ASCO 2025
- Data support that targeting NRP1 with antisense oligonucleotides is a promising therapeutic strategy for solid cancers where current immunotherapies show limited benefit
- SECN-15 demonstrates meaningful anti-tumor activity as well as excellent safety and tolerability profile in vivo
- Gastric cancer selected as a lead indication for planned Phase I/II clinical trial
Martinsried (Munich), Germany, May 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, will present new data on the company’s lead program, SECN-15, a potential first-in-class antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 4 in Chicago, Illinois, USA.
Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement
Martinsried (Munich), Germany, May 12, 2025 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced the signing of a research and option agreement for a scientific and strategic collaboration with one of Curie.Bio’s portfolio companies.
Secarna Pharmaceuticals adds leading expert to Scientific Advisory Board with appointment of Prof. Dr. Vignali
- Prof. Dr. Dario A.A. Vignali brings vast knowledge from groundbreaking cancer research work in immune regulation and the immunosuppressive tumor microenvironment
- His expertise in the field of immuno-oncology and in particular NRP1, the target of Secarna’s lead asset, SECN-15, will help translate the Company’s scientific discoveries into significant clinical strategies
- Prof. Vignali joins current SAB members Prof. Dr. Alexander M.M. Eggermont and Prof. Dr. Alfred Zippelius, both cancer research key opinion leaders
BayOConnect 2025
With our AI-empowered OligoCreator® platform we streamline the identification and characterization of best-in-class oligonucleotide therapies to deliver transformative treatments and hope to patients in need by pushing the boundaries of medical science and transforming lives for the better.
Konstantin Petropoulos, Ph.D., MBA
CEO